Efficacy and safety of fixed combinations of irbesartan/hydrochlorothiazide in older vs younger patients with hypertension uncontrolled with monotherapy

William Cushman, Joel M. Neutel, Elijah Saunders, George L. Bakris, Keith C. Ferdinand, Elizabeth O. Ofili, James R. Sowers, Robert Madder, Michael A. Weber

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Subgroup analysis of the Irbesartan/Hydrochlorothiazide Blood Pressure Reductions in Diverse Patient Populations (INCLUSIVE) trial evaluated the efficacy and safety of irbesartan/hydrochlorothiazide (HCTZ) fixed combinations in patients aged 65 years or older with uncontrolled systolic blood pressure (SBP) after ≥4 weeks of antihypertensive monotherapy. The INCLUSIVE trial was a prospective, open-label, single-arm trial carried out in 119 sites. Of 844 patients completing placebo treatment, 212 were aged 65 years or older. Participants received treatment with placebo (4-5 weeks), HCTZ 12.5 mg (2 weeks), irbesartan/HCTZ 150/12.5 mg (8 weeks), and then irbesartan/HCTZ 300/25 mg (8 weeks). From baseline to week 18 (n=184, intent-to-treat population), mean change in SBP was -23.0±13.3 mm Hg (P<.001) and diastolic BP (DBP) was -10.9±7.7 mm Hg (P<.001). Mean SBP/DBP at study end was 134.0±14.7/75.1±8.4 mm Hg, and SBP, DBP, and SBP/DBP goal was achieved in 73%, 96%, and 72% of patients, respectively. Irbesartan/HCTZ combination therapy allowed SBP goal attainment in 73% of patients aged 65 years or older whose hypertension was previously uncontrolled with antihypertensive monotherapy.(Am J Geriatr Cardiol. 2008;17:27-36).

Original languageEnglish (US)
Pages (from-to)27-36
Number of pages10
JournalAmerican Journal of Geriatric Cardiology
Volume17
Issue number1
DOIs
StatePublished - Jan 1 2008

Fingerprint

irbesartan
Hydrochlorothiazide
Blood Pressure
Hypertension
Safety
Antihypertensive Agents

All Science Journal Classification (ASJC) codes

  • Gerontology
  • Health Policy
  • Geriatrics and Gerontology
  • Cardiology and Cardiovascular Medicine

Cite this

Efficacy and safety of fixed combinations of irbesartan/hydrochlorothiazide in older vs younger patients with hypertension uncontrolled with monotherapy. / Cushman, William; Neutel, Joel M.; Saunders, Elijah; Bakris, George L.; Ferdinand, Keith C.; Ofili, Elizabeth O.; Sowers, James R.; Madder, Robert; Weber, Michael A.

In: American Journal of Geriatric Cardiology, Vol. 17, No. 1, 01.01.2008, p. 27-36.

Research output: Contribution to journalArticle

Cushman, William ; Neutel, Joel M. ; Saunders, Elijah ; Bakris, George L. ; Ferdinand, Keith C. ; Ofili, Elizabeth O. ; Sowers, James R. ; Madder, Robert ; Weber, Michael A. / Efficacy and safety of fixed combinations of irbesartan/hydrochlorothiazide in older vs younger patients with hypertension uncontrolled with monotherapy. In: American Journal of Geriatric Cardiology. 2008 ; Vol. 17, No. 1. pp. 27-36.
@article{583eae303b7641a2bac84f7ce7cedad3,
title = "Efficacy and safety of fixed combinations of irbesartan/hydrochlorothiazide in older vs younger patients with hypertension uncontrolled with monotherapy",
abstract = "Subgroup analysis of the Irbesartan/Hydrochlorothiazide Blood Pressure Reductions in Diverse Patient Populations (INCLUSIVE) trial evaluated the efficacy and safety of irbesartan/hydrochlorothiazide (HCTZ) fixed combinations in patients aged 65 years or older with uncontrolled systolic blood pressure (SBP) after ≥4 weeks of antihypertensive monotherapy. The INCLUSIVE trial was a prospective, open-label, single-arm trial carried out in 119 sites. Of 844 patients completing placebo treatment, 212 were aged 65 years or older. Participants received treatment with placebo (4-5 weeks), HCTZ 12.5 mg (2 weeks), irbesartan/HCTZ 150/12.5 mg (8 weeks), and then irbesartan/HCTZ 300/25 mg (8 weeks). From baseline to week 18 (n=184, intent-to-treat population), mean change in SBP was -23.0±13.3 mm Hg (P<.001) and diastolic BP (DBP) was -10.9±7.7 mm Hg (P<.001). Mean SBP/DBP at study end was 134.0±14.7/75.1±8.4 mm Hg, and SBP, DBP, and SBP/DBP goal was achieved in 73{\%}, 96{\%}, and 72{\%} of patients, respectively. Irbesartan/HCTZ combination therapy allowed SBP goal attainment in 73{\%} of patients aged 65 years or older whose hypertension was previously uncontrolled with antihypertensive monotherapy.(Am J Geriatr Cardiol. 2008;17:27-36).",
author = "William Cushman and Neutel, {Joel M.} and Elijah Saunders and Bakris, {George L.} and Ferdinand, {Keith C.} and Ofili, {Elizabeth O.} and Sowers, {James R.} and Robert Madder and Weber, {Michael A.}",
year = "2008",
month = "1",
day = "1",
doi = "10.1111/j.1076-7460.2007.07317.x",
language = "English (US)",
volume = "17",
pages = "27--36",
journal = "American Journal of Geriatric Cardiology",
issn = "1076-7460",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Efficacy and safety of fixed combinations of irbesartan/hydrochlorothiazide in older vs younger patients with hypertension uncontrolled with monotherapy

AU - Cushman, William

AU - Neutel, Joel M.

AU - Saunders, Elijah

AU - Bakris, George L.

AU - Ferdinand, Keith C.

AU - Ofili, Elizabeth O.

AU - Sowers, James R.

AU - Madder, Robert

AU - Weber, Michael A.

PY - 2008/1/1

Y1 - 2008/1/1

N2 - Subgroup analysis of the Irbesartan/Hydrochlorothiazide Blood Pressure Reductions in Diverse Patient Populations (INCLUSIVE) trial evaluated the efficacy and safety of irbesartan/hydrochlorothiazide (HCTZ) fixed combinations in patients aged 65 years or older with uncontrolled systolic blood pressure (SBP) after ≥4 weeks of antihypertensive monotherapy. The INCLUSIVE trial was a prospective, open-label, single-arm trial carried out in 119 sites. Of 844 patients completing placebo treatment, 212 were aged 65 years or older. Participants received treatment with placebo (4-5 weeks), HCTZ 12.5 mg (2 weeks), irbesartan/HCTZ 150/12.5 mg (8 weeks), and then irbesartan/HCTZ 300/25 mg (8 weeks). From baseline to week 18 (n=184, intent-to-treat population), mean change in SBP was -23.0±13.3 mm Hg (P<.001) and diastolic BP (DBP) was -10.9±7.7 mm Hg (P<.001). Mean SBP/DBP at study end was 134.0±14.7/75.1±8.4 mm Hg, and SBP, DBP, and SBP/DBP goal was achieved in 73%, 96%, and 72% of patients, respectively. Irbesartan/HCTZ combination therapy allowed SBP goal attainment in 73% of patients aged 65 years or older whose hypertension was previously uncontrolled with antihypertensive monotherapy.(Am J Geriatr Cardiol. 2008;17:27-36).

AB - Subgroup analysis of the Irbesartan/Hydrochlorothiazide Blood Pressure Reductions in Diverse Patient Populations (INCLUSIVE) trial evaluated the efficacy and safety of irbesartan/hydrochlorothiazide (HCTZ) fixed combinations in patients aged 65 years or older with uncontrolled systolic blood pressure (SBP) after ≥4 weeks of antihypertensive monotherapy. The INCLUSIVE trial was a prospective, open-label, single-arm trial carried out in 119 sites. Of 844 patients completing placebo treatment, 212 were aged 65 years or older. Participants received treatment with placebo (4-5 weeks), HCTZ 12.5 mg (2 weeks), irbesartan/HCTZ 150/12.5 mg (8 weeks), and then irbesartan/HCTZ 300/25 mg (8 weeks). From baseline to week 18 (n=184, intent-to-treat population), mean change in SBP was -23.0±13.3 mm Hg (P<.001) and diastolic BP (DBP) was -10.9±7.7 mm Hg (P<.001). Mean SBP/DBP at study end was 134.0±14.7/75.1±8.4 mm Hg, and SBP, DBP, and SBP/DBP goal was achieved in 73%, 96%, and 72% of patients, respectively. Irbesartan/HCTZ combination therapy allowed SBP goal attainment in 73% of patients aged 65 years or older whose hypertension was previously uncontrolled with antihypertensive monotherapy.(Am J Geriatr Cardiol. 2008;17:27-36).

UR - http://www.scopus.com/inward/record.url?scp=40949113795&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40949113795&partnerID=8YFLogxK

U2 - 10.1111/j.1076-7460.2007.07317.x

DO - 10.1111/j.1076-7460.2007.07317.x

M3 - Article

VL - 17

SP - 27

EP - 36

JO - American Journal of Geriatric Cardiology

JF - American Journal of Geriatric Cardiology

SN - 1076-7460

IS - 1

ER -